This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Celyad SA (CYAD) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Celyad SA (CYAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CNS Pharmaceuticals, Inc. (CNSP) and Celyad SA (CYAD) have performed compared to their sector so far this year.
5 Beaten-Down Biotech Bets to Bounce Back in 2022
by Indrajit Bandyopadhyay
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer
by Zacks Equity Research
Celyad Oncology (CYAD) collaborates with Merck to evaluate its CAR-T candidate, CYAD-101,combined with the latter's Keytruda in microsatellite stable refractory metastatic colorectal cancer.
Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate
by Zacks Equity Research
Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.
5 Health Care Stocks to Bet on as Coronavirus Woes Linger
by Sreoshi Bera
The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.
All You Need to Know About Celyad SA (CYAD) Rating Upgrade to Strong Buy
by Zacks Equity Research
Celyad SA (CYAD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top Ranked Momentum Stocks to Buy for April 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 20th
What Makes Celyad SA (CYAD) a New Buy Stock
by Zacks Equity Research
Celyad SA (CYAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Celyad SA (CYAD) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Celyad SA (CYAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Celyad Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Celyad has been struggling lately, but the selling pressure may be coming to an end soon.
Celyad SA Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Celyad has been struggling lately, but the selling pressure may be coming to an end soon.
Celyad Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Celyad has been struggling lately, but the selling pressure may be coming to an end soon.
Celyad (CYAD) Jumps: Stock Rises 6.8%
by Zacks Equity Research
Celyad (CYAD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
3 Biotech Stocks That More than Doubled Year to Date
by Arpita Dutt
Here is a look at Puma (PBYI) and two other biotech stocks that have recorded massive gains so far in 2017.